Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720024 | 0.88 | — | — | |
| SCHEMBL17466319 | 0.87 | — | — | |
| SCHEMBL16672510 | 0.86 | — | — | |
| SCHEMBL8327368 | 0.86 | — | — | |
| SCHEMBL9464719 | 0.86 | — | — | |
| SCHEMBL17469890 | 0.84 | — | — | |
| SCHEMBL18840072 | 0.81 | — | — | |
| Ethylene Glycol SCHEMBL21809116 | 0.81 | — | — | |
| SCHEMBL17469925 | 0.81 | FNTA (0.33) | — | |
| SCHEMBL17456615 | 0.78 | CA1 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1104699-A | — | — | None | — | — | JP | disclosed |
| EP-3124490-A1 | HIGH STABILITY POLYIONIC LIQUID SALTS | Sigma-Aldrich Co. LLC (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2114969-B1 | HIGH STABILITY POLYIONIC LIQUID SALTS | SIGMA ALDRICH CO LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160027592-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTRICITY STORAGE DEVICE USING SAME | UBE INDUSTRIES, LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| EP-2301902-B1 | HIGH-EARLY-STRENGTH AGENT FOR HYDRAULIC COMPOSITION | KAO CORP (JP) | 2015-02-25 | — | — | EP | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| WO-2008095069-A2 | HIGH STABILITY POLYIONIC LIQUID SALTS | SIGMA-ALDRICH CO. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1614432-A2 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-11 | — | — | EP | disclosed |
| WO-1999007339-A1 | COMPOSITIONS FOR VISUALLY IMPROVING SKIN | THE PROCTER & GAMBLE COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
| US-5821237-A | ACTIVE MATERIALS CONTAIN AT LEAST ONE CYCLIC POLYANIONIC POLYOL, AT LEAST ONE SULFYDRYL COMPOUND AND AT LEAST ONE ZWITTERIONIC SURFACTANT | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0814842-A1 | METHOD FOR TREATING AMYLOIDOSIS | Queen's University at Kingston (CA) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028187-A1 | METHOD FOR TREATING AMYLOIDOSIS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-09-19 | — | — | WO | disclosed |
| JP-H01104699-A | PRODUCTION OF HIGHER FATTY MONOGLYCERIDE MONOSULFATE | COLGATE PALMOLIVE CO | 1989-04-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | CA2 1085/4885 |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | CA2 1085/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | CA2 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.